RemeGen Past Earnings Performance

Past criteria checks 0/6

RemeGen's earnings have been declining at an average annual rate of -28.7%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 44.5% per year.

Key information

-28.7%

Earnings growth rate

-15.7%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate44.5%
Return on equity-65.5%
Net Margin-102.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How RemeGen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688331 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,522-1,5521,1621,602
30 Jun 241,402-1,5881,1111,572
31 Mar 241,245-1,5361,1191,388
31 Dec 231,083-1,5111,0871,306
30 Sep 23972-1,3411,0591,178
30 Jun 23844-1,2139731,073
31 Mar 23790-1,0368211,014
31 Dec 22772-999718982
30 Sep 221,879276642849
30 Jun 221,745231582834
31 Mar 221,570174543793
31 Dec 211,424276483711
30 Sep 21115-912378663
30 Jun 2129-892338604
31 Mar 214-783291527
31 Dec 200-698242466
30 Sep 200-588175423
30 Jun 200-478109380
31 Mar 200-44284358
31 Dec 190-43069352
31 Dec 1811-27029216

Quality Earnings: 688331 is currently unprofitable.

Growing Profit Margin: 688331 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688331 is unprofitable, and losses have increased over the past 5 years at a rate of 28.7% per year.

Accelerating Growth: Unable to compare 688331's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688331 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 688331 has a negative Return on Equity (-65.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:11
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RemeGen Co., Ltd. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Shun Kei LawCCB International Securities Limited